As filed with the U.S. Securities and Exchange Commission under
the Securities Act of 1933, as amended, on January 6, 2025.

Registration No. 333-281170

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

__________________________________

AMENDMENT NO. 6
TO
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

__________________________________

Drugs Made In America Acquisition Corp.
(Exact name of registrant as specified in its charter)

__________________________________

Cayman Islands		6770		99-2394788
(State or other jurisdiction of incorporation or organization)		(Primary Standard Industrial Classification Code Number)		(I.R.S. Employer Identification Number)

Lynn Stockwell
Chief Executive Officer and Executive Chair
Drugs Made In America Acquisition Corp.
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301
(954) 870-3099

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
__________________________________

Copies to:

Mitchell S. Nussbaum G. Alex Weniger-Araujo Loeb & Loeb LLP 345 Park Avenue New York, NY 10154 Tel: (212) 407-4000

Michael J. Blankenship Winston & Strawn LLP 800 Capitol Street, Suite 2400 Houston, Texas 77002 Tel: (713) 651-2600

__________________________________

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging growth company		☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

ITEM 16.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

(a)     Exhibits.    The following exhibits are being filed herewith:

Exhibit		Description
1.1*		Form of Underwriting Agreement
3.1*		Memorandum and Articles of Association
3.2*		Amended and Restated Memorandum and Articles of Association
3.3*		Form of Second Amended and Restated Memorandum and Articles of Association
4.1*		Specimen Unit Certificate
4.2*		Specimen Ordinary Share Certificate
4.3*		Specimen Rights Certificate (included in Exhibit 4.4)
4.4*		Form of Rights Agreement between VStock Transfer, LLC and the Registrant
5.1*		Opinion of Maples and Calder (Cayman) LLP
5.2*		Opinion of Loeb & Loeb LLP
10.1*		Amended and Restated Promissory Note, dated as of December 5, 2024, issued to Drugs Made In America Acquisition LLC
10.2*		Securities Subscription Agreement, dated June 14, 2024, between the Registrant and Drugs Made In America Acquisition LLC
10.3*		Form of Letter Agreement among the Registrant, its directors and officers, and Drugs Made In America Acquisition LLC
10.4*		Form of Investment Management Trust Agreement among Wilmington Trust National Association, VStock Transfer, LLC and the Registrant
10.5*		Form of Registration Rights Agreement between the Registrant and certain security holders
10.6*		Form of Private Units Purchase Agreement between the Registrant and Drugs Made In America Acquisition LLC
10.7*		Form of Indemnity Agreement
10.8*		Form of Administrative Services Agreement by and between the Registrant and an affiliate of the Registrant
14*		Form of Code of Conduct
23.1**		Consent of MaloneBailey, LLP
23.2*		Consent of Maples and Calder (Cayman) LLP (included in Exhibit 5.1)
23.3*		Consent of Loeb & Loeb LLP (included in Exhibit 5.2)
99.1*		Consent of Catherine Do
99.2*		Consent of G. Sridhar Prasad
99.3*		Consent of Myron W. Shulgan
99.4*		Form of Audit Committee Charter
99.5*		Form of Compensation Committee Charter
107.1*		Filing Fee Table

____________

*        Previously filed.

**      Filed herewith.

(b)    Financial Statements.    See page F-1 for an index to the financial statements and schedules included in the registration statement.

ITEM 17.  UNDERTAKINGS.

(a)     The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

(b)    Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore,

unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

(c)     The undersigned registrant hereby undertakes that:

(1)    For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

(2)    For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4)    For the purpose of determining liability under the Securities Act of 1933 of any purchaser, if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

(5)    For the purpose of determining liability of a registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of an undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i)     any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii)    any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by an undersigned registrant;

(iii)   the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv)   any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Amendment No. 6 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fort Lauderdale, State of Florida, on the 6th day of January, 2025.

		Drugs Made In America Acquisition Corp.
		By:		/s/ Lynn Stockwell
		Name:		Lynn Stockwell
		Title:		Chief Executive Officer and Executive Chair

Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 6 to the Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

Name		Position		Date
/s/ Lynn Stockwell		Chief Executive Officer and Executive Chair		January 6, 2025
Lynn Stockwell		(principal executive officer)
/s/ Glenn Worman		Chief Financial Officer		January 6, 2025
Glenn Worman		(principal financial and accounting officer)